News
ORGO
2.350
+2.84%
0.065
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Caterpillar Inc. Fell 6.6% to $339.37 on Thursday. Caterpillar reported better-than-expected first-quarter EPS but missed revenue estimates. Barfresh Food Group, Inc. Shares surged 87.2% after the company reported better than expected results. Chicken Soup for the Entertainment for the Soul Entertainment dropped 75%.
Benzinga · 1d ago
CETX, ATNI and MNY among mid-day movers
On the Move CETX, ATNI and MNY among mid-day movers. Loar Holdings and Safe & Green Holdings Corp are among the Gainers. E-Home Household Service Holdings Ltd. Is one of the losers in the SA market.
Seeking Alpha · 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Aclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. Akso Health Group ( NASDAQ:AHG) shares increased by 29.87%. Processa Pharma (NASdaq:PCSA) stock increased by 43.18%. Cyclacel Pharmaceuticals stock declined by 33.1% during the session.
Benzinga · 1d ago
Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Healthcare On the Move: Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers. S&P 500 Health Care Sector -0.23% to 1637.36. Pharmaceuticals and Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 1d ago
Weekly Report: what happened at ORGO last week (0415-0419)?
Weekly Report · 4d ago
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
First quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th. Organogenesis Holdings Inc. Is a leading regenerative medicine company focused on the Advanced Wound Care and Surgical & Sports Medicine markets. The company's shares are listed on the Nasdaq.
Barchart · 04/16 06:30
Weekly Report: what happened at ORGO last week (0408-0412)?
Weekly Report · 04/15 09:31
Weekly Report: what happened at ORGO last week (0401-0405)?
Weekly Report · 04/08 09:33
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case
Organogenesis Holdings Inc. Is a leading regenerative medicine company focused on the Advanced Wound Care and Surgical & Sports Medicine markets. The U.S. District Court for the Eastern District of New York granted the Company’s motion to dismiss all claims asserted.
Barchart · 04/03 06:30
Weekly Report: what happened at ORGO last week (0325-0329)?
Weekly Report · 04/01 09:33
Weekly Report: what happened at ORGO last week (0318-0322)?
Weekly Report · 03/25 09:34
Buy Rating Affirmed for Organogenesis Holdings Amid Stable Product Pricing and Positive Market Dynamics
Analyst Ryan Zimmerman of BTIG maintained a Buy rating on Organogenesis Holdings (ORGO – Research Report) with a price target of $6.00. Zimmerman is a 5-star analyst with an average return of 10.6% and a 49.18% success rate. The company is a regenerative medical company.
TipRanks · 03/19 10:19
Weekly Report: what happened at ORGO last week (0311-0315)?
Weekly Report · 03/18 09:33
Weekly Report: what happened at ORGO last week (0304-0308)?
Weekly Report · 03/11 09:32
Weekly Report: what happened at ORGO last week (0226-0301)?
Weekly Report · 03/04 09:33
Organogenesis Holdings Price Target Maintained With a $5.00/Share by Cantor Fitzgerald
Dow Jones · 03/01 14:47
Cantor Fitzgerald Reiterates Overweight on Organogenesis Hldgs, Maintains $5 Price Target
Benzinga · 03/01 14:35
Organogenesis Holdings: A Buy Rating with Anticipated Turnaround and Growth Prospects
Analyst Ryan Zimmerman of BTIG maintained a Buy rating on Organogenesis Holdings (ORGO – Research Report) with a price target of $6. Zimmerman is optimistic about the company's future growth. The company's guidance for fiscal year 2024 suggests a modest recovery in revenue growth.
TipRanks · 03/01 11:58
Organogenesis Holdings GAAP EPS of $0.00 in-line, revenue of $99.7M misses by $9.35M
Seeking Alpha · 02/29 21:21
Recap: Organogenesis Hldgs Q4 Earnings
Organogenesis Hldgs reported its Q4 earnings on February 29, 2024. The company missed its earnings estimate by 0.0% and missed revenue by $15.87 million. Organogenesis hldgs is expected to announce its earnings on Thursday. Last quarter the company beat on EPS by $0.04.
Benzinga · 02/29 21:15
More
Webull provides a variety of real-time ORGO stock news. You can receive the latest news about Organogenesis Hldgs Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORGO
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.